Cargando cotizaciones...
Previsión
| Comprar |
17 |
| Mantener |
15 |
| Vender |
4 |
Debates en la comunidad
- Ticker
Generales Problem bei Aktien wird immer nur 1 zufälliger Ticker angezeigt. Mit Pech ist der Ticker veraltet oder inaktiv. Beispiel AstraZeneca (ISIN: GB0009895292): Statt des seit fast einem Jahr…
M Mars III en Terminal
2 0 - Novo Nordisk
Moin, Umfrage: Wer hatte alles die Faxen dicke und hat abgestoßen und wer hat die “Chance” genutzt und seinen Buy-In gedrückt? 😅 🏃♂️💨💨💨 ...raus da.... 💰💸 ...all in... 🫷...stehe (noch) an der…
s sanzen I en Schnack
3 20
Noticias Ir al feed de noticias
AstraZeneca beats expectations after strong quarter in cancer drugs
AstraZeneca reported third-quarter revenue up 7% to about $16.2 billion and a group net profit of roughly $3.1 billion (around +25%). Adjusted earnings per share beat analysts’ expectations; the cancer drugs division grew 17% to just under $7.8 billion and accounted for almost half of sales, while revenue in the cardiovascular, renal and metabolism area fell by about one fifth to $2.6 billion. CEO Pascal Soriot confirmed the targets for 2026 and 2030; for the current year, currency‑adjusted sales growth in the mid‑to‑high single digits and a low‑double‑digit increase in adjusted earnings per share are expected. The shares jumped sharply after the results. » Más en finanzen.net
Astrazeneca beats expectations with strong Q3 thanks to cancer drugs
Astrazeneca reports a 7% rise in third-quarter revenue to about $16.2 billion and a 25% increase in net income to $3.1 billion, both above market expectations. Revenue was driven by cancer drugs, whose sales rose 17% to nearly $7.8 billion, making up almost half of group sales, while cardiovascular, renal and metabolic medicines fell by around one fifth. CEO Pascal Soriot reaffirms targets for 2026 and 2030; analysts at Bernstein, Jefferies and UBS confirm or raise buy ratings and lift price targets. The stock jumped sharply, topping the 200-day moving average; the dividend yield is around 2.0%. » Más en deraktionaer.de
AstraZeneca surprises with strong revenue and profit growth
AstraZeneca reported a 7% rise in third-quarter revenue to about $16.2 billion and a roughly 25% increase in net profit to $3.1 billion. Sales of cancer drugs rose 17% to just under $7.8 billion, while revenues in the cardiovascular, renal and metabolic segment fell by about one-fifth to $2.6 billion. CEO Pascal Soriot said the company is on track to meet its 2026 and 2030 targets; for 2024 AstraZeneca expects currency-adjusted mid- to high-single-digit revenue growth and low-double-digit growth in adjusted earnings per share. In London the stock rose as much as about 2.9% and traded at £134.36. » Más en finanzen.net
AstraZeneca: EU approval for Enhertu in early HER2-positive breast cancer
The EU Commission has approved Enhertu from AstraZeneca and Daiichi Sankyo as monotherapy for patients with residual disease after surgically removed HER2‑positive early-stage breast cancer. The approval, the first for Enhertu with curative intent in the early-stage setting, is based on Phase III data that reduced the risk of recurrence or death. The AstraZeneca stock showed only a slight reaction to the news. » Más en finanzen.net
Astrazeneca and Oracle enter AI partnership to accelerate clinical research
Astrazeneca has agreed with Oracle on a collaboration that links Astrazeneca's scientific expertise with Oracle's real-world data, cloud and AI capabilities. The aim is to evaluate selected use cases, make clinical trials more efficient, generate evidence across the entire drug lifecycle and improve patient care. The cooperation is non-binding and is intended to help identify patients earlier and increase trial success rates. » Más en deraktionaer.de
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | diciembre de 2025 | YoY |
|---|---|---|
| Ingresos | 13,21 mil M | - |
| Beneficio bruto | 10,56 mil M | - |
| Beneficio neto | 1982,5 M | - |
| EBITDA | 3941,13 M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 267,21 mil M € |
Número de acciones | 1550,28 M |
Máximo/mínimo de 52 semanas | 190,13 € - 110,97 € |
Rentabilidad por dividendo | 1,66 % |
Dividendos TTM | 2,77 € |
Beta | 0,19 |
Ratio P/E | 25,95 |
Ratio PEG | 1,57 |
Ratio P/B | 5,57 |
Ratio P/S | 4,59 |
Perfil de la empresa
AstraZeneca PLC, una empresa biofarmacéutica, se centra en el descubrimiento, desarrollo, fabricación y comercialización de medicamentos con receta. Entre sus productos comercializados figuran Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso y Zoladex para oncología; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern y Xigduo/Xigduo XR para enfermedades cardiovasculares, renales y metabólicas; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort y Tudorza/Eklira/Bretaris para enfermedades respiratorias e inmunología; y Andexxa/Ondexxya, Kanuma, Soliris, Strensiq y Ultomiris para enfermedades raras. La compañía también comercializa Synagis para el virus sincitial respiratorio; Fluenz Tetra/FluMist Quadrivalent para la gripe; Seroquel IR/Seroquel XR para la esquizofrenia y el trastorno bipolar; Nexium y Losec/Prilosec para gastroenterología; y Vaxzevria y Evusheld para la covid-19. La empresa atiende a médicos de atención primaria y especialistas a través de distribuidores y oficinas de representación locales en el Reino Unido, el resto de Europa, las Américas, Asia, África y Australasia. Tiene un acuerdo de colaboración con Regeneron Pharmaceuticals, Inc. para investigar, desarrollar y comercializar medicamentos de molécula pequeña para la obesidad; con Neurimmune AG para desarrollar y comercializar NI006; con Ionis Pharmaceuticals, Inc. para desarrollar eplontersen, una terapia antisentido dirigida al hígado en fase III para el tratamiento de la amiloidosis por transtiretina; con Proteros Biostructures GmbH para descubrir conjuntamente nuevas moléculas pequeñas para el tratamiento de cánceres hematológicos; y con Sierra Oncology, Inc. para desarrollar y comercializar AZD5153. La compañía era anteriormente conocida como Zeneca Group PLC y cambió su nombre a AstraZeneca PLC en abril de 1999. AstraZeneca PLC se constituyó en 1992 y tiene su sede en Cambridge, Reino Unido.
| Nombre | AstraZeneca |
| CEO | Pascal Claude Roland Soriot |
| Sede | Cambridge,
Reino Unido |
| Sitio web | |
| Sector | Salud |
| Industria | Productos farmacéuticos |
| Salida a bolsa | 21/05/1993 |
| Empleados | 94.300 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
Pnk | AZNCF |
London Stock Exchange | AZN.L |
XETRA | ZEG.DE |
Sto | AZN.ST |
Frankfurt | ZEG.F |
Düsseldorf | ZEG.DU |
Hamburg | ZEG.HM |
London | AZN.L |
Stockholm | AZN.ST |
SIX | AZN.SW |
München | ZEG.MU |